Anne Wojcicki's nonprofit now controls 23andMe's assets. Following the company's Chapter 11 bankruptcy filing in March 2025, her organization, TTAM Research Institute, successfully acquired substantially all of 23andMe's key assets—including its Personal Genome Service, Research Services, and telehealth subsidiary Lemonaid Health—for $305 million. This deal, approved by the court in late June or early July 2025, outbid competitors like Regeneron Pharmaceuticals and marked a dramatic comeback for Wojcicki, the company's co- founder and former CEO.

Ownership Timeline

23andMe's path to this point reads like a biotech thriller—full of innovation, regulatory hurdles, and financial twists.

  • 2006 Founding : Co-founded by Anne Wojcicki, Linda Avey, and Paul Cusenza in California, revolutionizing direct-to-consumer DNA testing.
  • 2021 Publicly Traded : Went public via SPAC merger with VG Acquisition Corp, trading as "ME" on Nasdaq; Wojcicki remained CEO with significant influence.
  • 2023-2024 Challenges : Hit by a major data breach, declining revenues (down to $219.6M in FY2024), and mounting debts leading to bankruptcy.
  • 2025 Bankruptcy Auction : Initial win by Regeneron ($265M bid) sparked lawsuits from 27 state AGs over consumer data; Wojcicki reopened the auction and clinched the win with her fully self-funded $305M offer through TTAM.
  • Current Status (Feb 2026) : Transaction closed post-court approval; TTAM now owns the core assets, ensuring Wojcicki regains stewardship of the vast genetic database she helped build.

This shift addresses privacy fears, as Wojcicki's nonprofit structure prioritizes research over pure profit, though public forums buzz with debates on data security.

Key Deal Details

Here's a breakdown of the acquisition:

Aspect| Details
---|---
Buyer| TTAM Research Institute (Wojcicki-led nonprofit) 15
Assets Acquired| PGS, Research Services, Lemonaid Health—nearly all operations 9
Price| $305M (self-funded by Wojcicki, no external Fortune 500 backer confirmed) 7
Rival Bid| Regeneron at $256M-$265M, blocked by legal pushback 9
Timeline| Bankruptcy March 2025; auction win June 2025; court OK July 2025 13

What It Means Now

Privacy and Future Focus : Customers worried about their DNA data can breathe easier—Wojcicki's history suggests continuity in user-centric policies, unlike a pharma giant's potential pivot. Trending discussions on forums highlight relief over avoiding Regeneron, with some speculating on expanded research (e.g., drug discovery via the 15M+ user database).

From multiple viewpoints:

  • Optimists : "Wojcicki's buyback stabilizes the company; expect new health insights soon." (Echoed in tech podcasts).
  • Skeptics : Concerns linger on bankruptcy's root causes—data breaches and market saturation—wondering if TTAM can turn tides.
  • Users : Many deleted data post-breach; remaining samples power ongoing ancestry/health reports.

"Wojcicki’s nonprofit TTAM Research Institute will purchase 'substantially all' of San Francisco-based 23andMe’s assets for $305 million."

This saga underscores biotech's volatility, but Wojcicki's move keeps 23andMe's mission alive: empowering personal genomics.

TL;DR : Anne Wojcicki, via her TTAM nonprofit, owns 23andMe's core assets post-2025 bankruptcy buyout for $305M—current as of early 2026.

Information gathered from public forums or data available on the internet and portrayed here.